Taysha Gene Therapies, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Taysha Gene Therapies, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 291% in 3 years; of every extra $100 of sales, $784 became extra profit. Higher than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-29.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 64% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$784Sales grew 291% in 3 years; of every extra $100 of sales, $784 became extra profit.
Higher than 96% of Healthcare companies in United States.
Asset Productivity Ratio
+291% / +172%In 3 years sales changed by +291% while total assets changed by +172%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-49.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 73% of Healthcare companies in United States.
Cash Cushion Ratio
+19%Cash, after subtracting all debt, equals 19% of its market value (net cash).
Higher than 62% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Taysha Gene Therapies, Inc. made a loss over the last year. Taysha Gene Therapies, Inc. owes $0.18 for every $1 it owns. Taysha Gene Therapies, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTaysha Gene Therapies, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.37The share price is 3.37 times Taysha Gene Therapies, Inc.'s book value per share, higher than 60% of Healthcare companies in United States.
Market cap
$1.3 BThe total market value of all of Taysha Gene Therapies, Inc.'s shares at today's price (share price × number of shares), larger than 67% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$387 MWhat Taysha Gene Therapies, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.19Net worth divided by the number of shares. The share price of $4.00 is 3.4 times this, which is the P/B above.
Return on equity (ROE)
-47.1%Taysha Gene Therapies, Inc. lost 47.1% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
Owes vs Owns
0.18×Taysha Gene Therapies, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Dividend yield
NoneTaysha Gene Therapies, Inc. does not currently pay a dividend.
Revenue growth
+17%Revenue rose 17% in the year to Dec 2025, and grew 57% a year on average over 3 years.
Profit growth
LossTaysha Gene Therapies, Inc. made a loss in each of the last two years.
Profit margin
-1115.3%Taysha Gene Therapies, Inc. lost $1115 for every $100 of revenue.
Interest cover
Not coveredTaysha Gene Therapies, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashTaysha Gene Therapies, Inc. held $250 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Taysha Gene Therapies, Inc.: $1.3 B ÷ $387 M (30 Jun 2026) = 3.4.
What is Taysha Gene Therapies, Inc.'s return on equity?
Taysha Gene Therapies, Inc. lost 47.1% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
How much does Taysha Gene Therapies, Inc. owe compared with what it owns?
Taysha Gene Therapies, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Does Taysha Gene Therapies, Inc. pay a dividend?
No. Taysha Gene Therapies, Inc. does not currently pay a dividend.
Is Taysha Gene Therapies, Inc.'s revenue growing?
Revenue rose 17% in the year to Dec 2025, and grew 57% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.